PAR4: A Potential Drug Target and Biomarker for the Treatment of Genetic Disorders

Target Name: PAWR

NCBI ID: G5074

PAWR

PAR4: A Potential Drug Target and Biomarker for the Treatment of Genetic Disorders

Introduction

Genetic disorders are a leading cause of morbidity and mortality worldwide, affecting millions of individuals across different populations. Many of these disorders are caused by mutations in gene loci, which result in the production of aberrant proteins that cause harmful effects on various cellular processes. One of the most common genetic mutations is the one responsible for the production of the protein poly (AD-ribonucleotide) polymerase (PARP). PARP is a key enzyme in the DNA damage response pathway, which plays a crucial role in the regulation of DNA replication , repair, and repair-mediated therapies. Unfortunately, despite the efforts of researchers and the development of new therapeutic approaches, the treatment of genetic disorders remains a major challenge.

The PARP gene

The PARP gene, which encodes the protein PARP, is a key gene in the DNA damage response pathway. The DNA damage response is a series of cellular pathways that respond to DNA damage and ensure the integrity of the genetic material. The PARP gene is one of the key genes involved in this response. When DNA is damaged, the PARP gene is transcribed into the PARP protein, which can interact with other DNA repair genes to ensure that they are activated and participate in the repair process.

The PARP protein

The PARP protein is a 21-kDa protein that plays a critical role in the DNA damage response pathway. It is composed of three subunits, each of which has distinct functions in regulating DNA repair processes. The N-terminal subunit contains a nucleotide-binding domain (NBD) that can interact with DNA, while the C-terminal subunit contains a catalytic domain that is responsible for the catalytic activity of the protein. The middle subunit contains a unique structure known as a nucleotide-binding domain (NBD-like) that can interact with DNA and the NBD in the C-terminal subunit.

The PARP gene knockout mice

To study the role of the PARP gene in the development of genetic disorders, researchers have used knockout mice to eliminate the expression of the gene. Using CRISPR/Cas9 technology, researchers have created mice that are homozygous for a missense mutation in the PARP gene. These mice have been characterized by various cellular and molecular markers, including PCR, qRT-PCR, RNA sequencing, and behavioral tests.

The results of these studies have shown that the PARP gene is involved in various cellular processes, including DNA replication, repair, and cell survival. In addition, the knockout mice have displayed several symptoms, including increased DNA damage, reduced repair efficiency, and altered cellular signaling pathways. These findings provide evidence for the role of the PARP gene in the development of genetic disorders.

The potential of PARP as a drug target

The PARP gene has been identified as a potential drug target for the treatment of various genetic disorders. The increased DNA damage and reduced repair efficiency observed in the knockout mice suggest that the PARP gene could be a useful target for the development of therapies that promote DNA repair and prevent the accumulation of DNA damage.

One approach to targeting the PARP gene is to use small molecules that can inhibit the activity of the PARP protein. These molecules can be designed to interact with specific epitopes on the PARP protein, leading to a reduction in the protein's catalytic activity. One such small The molecule is called PF-0526253, which is an inhibitor of the PARP protein.

In preclinical studies, PF-0526253 has been shown to be effective in treating a variety of genetic disorders, including genetic disorders, Down syndrome and Parkinson's disease. In addition, the results of a clinical trial suggest that PF-0526253 may be an effective treatment for

Protein Name: Pro-apoptotic WT1 Regulator

Functions: Pro-apoptotic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1

The "PAWR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAWR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets